$AKBA Therapeutics $1.25 is already programmed - Long/Call

NASDAQ:AKBA   Akebia Therapeutics, Inc.
Fully expect a good earnings report. Positive news from the company. Nothing but good news as far as this company is concerned. Earnings posting this week, and will not disappoint. We could see a nice jump up here.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.